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Abstract: Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory demyelinating 
disorder of the central nervous system that leads to permanent neurological deficits. Current 
MS treatment regimens are insufficient to treat the irreversible neurological disabilities. 
Tremendous progress in the experimental and clinical applications of cell-based therapies 
has recognized stem cells as potential candidates for regenerative therapy for many 
neurodegenerative disorders including MS. Mesenchymal stem cells (MSC) and induced 
pluripotent stem cell (iPSCs) derived precursor cells can modulate the autoimmune response 
in the central nervous system (CNS) and promote endogenous remyelination and repair 
process in animal models. This review highlights studies involving the immunomodulatory 
and regenerative effects of mesenchymal stem cells and iPSCs derived cells in animal 
models, and their translation into immunomodulatory and neuroregenerative treatment 
strategies for MS. 








Multiple sclerosis (MS) is a chronic autoimmune, inflammatory, demyelinating, neurodegenerative 
disease of the central nervous system (CNS) of unknown etiology. The major clinical subtypes of MS are 
relapsing-remitting (RR) and secondary progressive (SP) MS. Clinically, RRMS represents the initial 
inflammatory phase characterized by partially reversible symptomatic attacks with temporary loss of 
motor functions, followed by periods of remission [1]. Approximately 50%–60% of these patients 
progress to SPMS in which the disease gradually evolves from intermittent attacks to slow, steady 
progressive worsening condition ultimately resulting in permanent disabilities resulting from massive 
axonal loss (seen in autopsy tissue sections). Primary progressive (PP) MS, the most severe subtype of 
MS, affects approximately 10% of all cases and manifests as progressive neurological decline in 
function from disease onset without remission [2]. The etiology of MS is believed to involve interplay 
between environmental factors such as vitamin D deficiency, UV light exposure, Epstein-Barr virus 
(EBV) infection [3], and individual genetic susceptibility [4]. 
2. Current Concepts in Multiple Sclerosis (MS) Pathology 
Pathological hallmarks of MS and experimental autoimmune encephalomyelitis (EAE) include  
CNS inflammation, gliosis, demyelination, and axonal loss. CNS pathology in patients is characterized 
by multifocal lesions, the MS plaques. In the acute phase, activated mononuclear cells, including 
lymphocytes, microglia, and macrophages destroy myelin and to a variable degree, oligodendrocytes. 
With time, gliosis develops, and plaques reach a burned-out stage consisting of demyelinated axons 
traversing glial scar tissue. The endogenous oligodendrocyte precursor cells (OPCs) proliferate robustly 
in response to demyelination, but fail to differentiate terminally, resulting in failure of remyelination. 
This is associated with axonal transection leading to permanent neurological deficits. If the inflammatory 
process is arrested at an early phase, plaques are partially remyelinated. Autopsy samples revealed that 
SPMS is associated with massive axon loss in the CNS and unmyelinated plaques [5,6]. 
Multiple cell types, including type 17 T helper cells (TH17), forkhead box P3 (FOXP3) regulatory T 
cells, B cells and macrophages are involved in MS disease pathogenesis [7]. It has been hypothesized 
that the first event in the pathogenesis of MS could be a viral infection in infancy. Activated 
T-lymphocytes generated during such an infection cross the blood-brain barrier and become sensitized 
to myelin antigens. Alternatively, lymphocytes are sensitized to viral proteins that share homology to 
myelin proteins. It is speculated that, after remaining latent for years, these autoreactive T cells re-enter 
the CNS through the impaired blood-brain barrier (BBB) and initiate an immune reaction against 
myelin. B-lymphocytes entering acute plaques become sensitized and produce antibodies to myelin 
antigens. Myelin, oligodendroglial cells, and axons are damaged by inflammatory cytokines, glutamate, 
nitric oxide (NO), and other toxic substances produced by microglia/macrophages. While the agents of 
CNS damage are the same, the immune reactions that initiate and propagate the process may vary among 
different forms of MS. 
Currently, there is no cure for MS. During the past decades, therapies for MS are either 
immunomodulatory or immunosuppressive [8]. Immunomodulatory and anti-inflammatory agents are 
effective in the relapsing–remitting stage by reducing the frequency of relapses, and decreasing the 
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formation of inflammatory lesions [9], but they do not influence the course of progressive MS and 
therefore are not sufficient enough to cure chronic neurological disability. The permanent neuronal loss 
that starts early and characterizes the progressive stage of MS remains untreatable. Therapeutic options 
such as Mitoxantrone for PPMS patients are limited to symptomatic treatments and the long-term 
prognosis is generally poor [10]. Future therapeutic strategies are aimed to achieve neuroprotection, 
remyelination and regeneration of new oligodendrocytes and neurons [11]. 
3. Stem Cells as a “Biological Solution to a Biological Problem” 
Stem cells are unspecialized cells in the body that retain the ability to generate cells of 
undifferentiated state identical to themselves, or of differentiating into other types of body cells with 
specialized functions [12]. There are various types of stem cells such as embryonic stem cells (ESCs), 
hematopoietic stem cells (HSCs), neural stem cells (NSCs), mesenchymal stem cells (MSCs) and 
induced pluripotent stem cells (iPSCs) [13]. Nowadays, with the great progression of biology and 
biotechnology, we are exploring “biological solutions to biological problems”. Stem cell therapy in 
axonal demyelination and neurological disability has had promising results in animal models as well  
as human patient clinical treatment [14]. Stem cell therapies may serve as potential therapy for 
neurodegenerative disease. Here, we review the recently published studies regarding preclinical and 
clinical use of MSCs and iPSCs in the treatment of MS, and their therapeutic mechanisms. Among the 
various types of stem cells, the efficacy and safety of MSCs have long been well established and 
characterized, but the recent advancements of iPSCs make them a promising candidate for autologous 
therapy. Both MSCs and iPSCs can be obtained from patients relatively easily and can be expanded for use. 
4. Mesenchymal Stem Cells (MSCs) 
MSCs were first isolated from bone marrow, characterized, and described by Friedenstein et al. in 
1968. These spindle-shaped, fibroblastic cells constitute about 0.01% to 0.001% of the entire nucleated 
cells of bone marrow. Caplan et al. introduced the term “mesenchymal stem cells” as they could be 
induced in vitro and in vivo to differentiate into other lines of mesodermal cells, including adipocytes, 
chondrocytes, connective stromal cells, and osteocytes-cells [15]. MSCs can be isolated from various 
sources such as bone marrow, amniotic fluid, dental pulp, adipose tissue [16], umbilical cord [17], 
synovial membranes, and peripheral blood, among which the main and the most frequently studied 
source is the bone marrow. MSCs are characterized by (i) the positive expression of CD105, CD90 and 
CD73 and negative expression for haematopoietic cell surface markers CD34, CD45, CD11a, CD19  
or CD79a, CD14 or CD11b, and human leukocyte antigen-DR (HLA-DR); (ii) under a specific 
stimulus, MSCs differentiate into osteocytes, adipocytes and chondrocytes in vitro. These criteria are 
currently used to purify MSC and to enable their expansion in vitro, without losing their differentiation 
capacity [18]. It has been recently reported that MSCs are able to differentiate into non-mesenchymal 
cell lineages, such as skeletal myocytes, neurons and cells of the visceral mesoderm, both in vitro and  
in vivo [17,19]. 
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5. Efficacy of MSCs in Mouse Experimental Autoimmune Encephalomyelitis (EAE) Mouse: 
Current Evidence 
In the EAE mouse model of multiple sclerosis, MSCs systematically injected at disease onset 
ameliorates myelin oligodendrocyte glycoprotein (MOG)-induced EAE, and decreases the infiltration 
of T-cells, B-cells and macrophages into the brain and spinal cord. MSCs can cause induction of T-cell 
anergy, since T cells extracted from the lymph nodes of MSC-treated mice are unable to proliferate 
after in vitro re-challenge with MOG peptide [20]. Systematic injection of MSCs can inhibit the in vivo 
production of pathogenic proteolipid protein (PLP)-specific antibodies and to suppress the encephalitogenic 
potential of PLP-specific T cells in passive-transfer experiments. The MSCs migrated to the spleen, as 
well as, to the inflamed CNS, where they exercised a neuroprotective effect on the axons [21]. In these 
studies, the therapeutic effect of MSCs depended on the release of anti-apoptotic, anti-inflammatory 
and trophic molecules, and, possibly, on the recruitment of local progenitors and their subsequent 
induction to differentiate into neural cells. As a trophic effect, the MSCs appeared to favor 
oligodendrogenesis by neural precursor cells [22]. However, recent reports also indicate that MSCs 
possess duality in immunomodulation [23,24] and even exacerbate the symptoms. In a pathogenic CD8+ 
T cells mediated MOG model of experimental autoimmune encephalomyelitis (EAE), a commonly used 
murine model of MS, MSCs deteriorated the disease and increased the CD8+ T cell presence in the 
brains of diseased mice [25]. 
Keypoints: Bone marrow (BM)-derived MSCs attenuate PLP and MOG induced EAE by 
suppressing PLP and MOG specific autoreactive T cells. 
6. Effect of the Inflammatory Environment of EAE on Endogenous MSCs 
It appears that the inflammatory environment imposes certain impact on BM-MSCs despite that 
BM-MSCs residing in the bone marrow are not directly implicated in the disease process. BM-MSCs 
isolated from EAE mice exhibited distinct morphology, elevated ratio of proliferation and apoptosis, 
differences in the adipogenesis and the osteogenesis induction, distinct expression profile of stromal 
markers [26] and different expression patterns on six histone-modifying genes compared to MSCs 
from control mice [27]. However, another report indicated that the inflammatory process did not exert 
any deleterious effect on the functional/biological properties of the BM-MSCs isolated from mice  
with EAE [28]. Intravenous administration of congenic BM-MSCs derived from EAE mice suppressed 
EAE development in transplanted mice, along with remarkable reduction of CNS inflammation and 
demyelination and, protection of the axons. There were no significant differences in these beneficial 
effects between EAE-BM-MSCs and MSCs obtained from wild-type syngeneic donors. These data 
showed conflicting findings regarding the therapeutic effectiveness of autologous BM-MSCs. 
In a recent study, adipose stromal/stem cell (ASCs) from mice with EAE and their syngeneic 
wild-type mice were cultured and expanded in vitro under standard cell culture condition. Although 
EAE-ASCs displayed a normal phenotype with typical MSCs surface antigen expression, they showed 
no therapeutic improvement on the disease progression in vivo. However, infusion of wild-type ASCs 
significantly ameliorated the disease course. Experimental results showed that EAE-ASCs mice 
acquired increased expression of monocyte chemoattractant protein-1 (MCP-1), a pro-inflammatory 
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cytokine [29]. MCP-1 can modulate the blood-brain barrier disruption and mononuclear leukocyte 
migration into the CNS [30]. It appears that the EAE-ASCs may have been irreversibly altered in the 
setting of chronic neuroinflammation and lost their therapeutic efficacy for the treatment of EAE mice. 
Mechanisms underlying the therapeutic discrepancy between MSCs obtained from different sources 
need further intensive research in the future to provide valuable information for autologous MSCs 
transplantation for the treatment of MS patients. 
However, EAE does not reflect all aspects of MS pathology, and murine derived MSCs do not share 
exactly the same properties with those of human origin. Additionally, MSCs in human studies were 
derived from MS patients where the inflammatory process was not comparable with those induced in 
acute EAE. Previous studies suggested that MSCs from patients with MS display a normal phenotype 
and are fully functional in terms of proliferation, in vitro differentiation and immunosuppressive 
capacity [31]. 
7. Efficacy of Genetically Engineered Human MSCs in Mouse EAE Models 
Human MSCs genetically engineered to over-express the anti-inflammatory cytokines promote 
curative effect in EAE models. IFN-β has a potent anti-inflammatory effect and has been used to treat 
RRMS for nearly two decades. Human BM-MSCs engineered to secret IFN-β (MSCs-IFN-β) via 
adenoviral transduction outperformed MSCs alone in decreasing inflammatory infiltration and 
demyelination in the lumbar spinal cord and inhibition of mice EAE onset [32]. MSCs-IFN-β exhibited 
augmented immunomodulatory effects and reduced further injury of BBB permeability in EAE mice 
via migrating into inflamed CNS [32]. Other cytokines also were exploited to strengthen the 
therapeutic effectiveness of MSCs. For example, human adipose-derived MSCs (Adi-MSCs) were 
engineered to over-express IL-4 attenuated symptoms in mice with EAE when administered early at 
the time of T-cell priming. The therapeutic efficacy was assumed to associate with a reduction in 
peripheral autoreactive T-cell responses and a shift from a pro- to an anti-inflammatory cytokine 
response [33]. Another study showed that Adi-IL-10-MSCs could prevent or delay the development of 
EAE if transplanted via intraperitoneal route early in the disease course to mice. An important 
mechanism involved might be inhibition of the maturation, cytokine expression profile and antigen 
presenting capacity of bone marrow-derived myeloid dendritic cells [34]. More cytokines and 
molecules such as interleukins, chemokines and their cognate receptors could be employed via 
transgenic technique to cooperate with the effects of MSCs either by their existence or absence. 
8. Mechanisms of Action of MSCs 
Much research has focused on exploiting the pleiotropic properties of MSCs as a basis for cell 
therapy for a variety of neurodegenerative disorders including MS [19]. The immunomodulatory, 
immunosuppressive, neurotrophic, and repair-promoting properties of MSCs [35] make them an 
attractive candidate for MS. The effects of MSCs on immunomodulation and remyelination are largely 
mediated by paracrine signals [22], and several secreted soluble molecules [20], TGF-β1 [36], IFN-γ [37], 
indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2, have been identified as important 
contributors to these beneficial effects. 
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9. Immunosuppressive Effects of MSCs 
Clonal expansion of CD4+ Th1 and Th17 lymphocytes are key pathogenic features of relapses in 
RRMS, and few of the current drugs prevent relapses by immunosuppression. Several studies have 
acknowledged the universal immunosuppressive activities of MSCs, but the specific mechanisms in the 
context of autoimmune disorders still needs to be fully elucidated (Figure 1). Direct interactions (via 
cell–cell contact) of MSCs with T-cells in vivo leads to the arrest of Th1-cell proliferation, inhibition  
of CD8+-mediated cytotoxicity and generation of anti-inflammatory CD4+ regulatory T-cells [38].  
As a consequence, impaired CD4+ T-cell activation translates into defective T-cell help for B-cell 
proliferation and differentiation to antibody-secreting cells. MSCs also inhibit pathogenic Th17 cells 
differentiation via IFN-γ-mediated suppressor of cytokine signaling 3 (SOCS3) activation [39]. 
 
Figure 1. The complex immunomodulatory functions of mesenchymal stem cells (MSCs) in 
the treatment of multiple sclerosis (MS). The different immune regulatory mechanisms, 
including pathogenic B cells, Th17 cells, macrophages, and beneficial regulatory T cells 
(Treg) are involved in shaping the MS pathology. Injection of MSCs improves experimental 
autoimmune encephalomyelitis (EAE) by imparting severe inhibitory effects (red lines in 
the picture) on performance of T cells, B cells and macrophages, through secretion of soluble 
factors, such as IFN-γ, TNF-α, IL-10, HGF, IL-6, PGE2 and HO1. MSCs can also promote 
an anti-inflammatory effect through promotion of Treg proliferation (green line). In addition, 
MSCs also positively modulate the functions of astrocytes, oligodendrocytes, and neuronal 
axons. HGF: hepatocyte growth factor; PGE2: prostaglandin E2; HO1: heme oxygenase 1. 
Several soluble immunosuppressive factors, either produced constitutively by MSCs or released 
following cross-talk with target cells, have been reported, including NO and IDO [37]. IDO induces the 
depletion of tryptophan from the local environment, which is an essential amino acid for lymphocyte 
proliferation. MSC-derived IDO was reported as a requirement to inhibit the proliferation of IFN-γ 
producing Th1 cells and, together with prostaglandin E2 (PGE2), to block natural killer (NK)-cell 
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activity [34]. In addition, IFN-γ, alone or in combination with TNF-α and IL-10, stimulates the 
production of chemokines by mouse MSCs that attract T-cells and stimulate the production of inducible 
nitric-oxide synthase (iNOS), which in turn inhibits T-cell activation through the production of  
NO [31]. It is worth noting that MSCs from IFN-γ receptor (IFN-γ-R1) deficient mice do not have 
immunosuppressive activity, which highlights the vital role of IFN-γ in the immunosuppressive  
function of MSC [31]. We conclude that MSCs have the potential to directly or indirectly inhibit 
disease-associated Th1, Th2, and Th17 cells as well as cytotoxic CD8+ lymphocytes but that many key 
questions regarding the, specificity, mechanistic basis, and predictable therapeutic value of these 
modulatory effects remain unanswered in the context of MS therapy. 
Keypoints: Both mouse and human BM-MSCs cause Th17 cell anergy, inhibit CD8+ T cell mediated 
cytotoxicity, and promote Treg cell generation in EAE. 
10. Immunomodulatory Action of MSCs in MS 
Th17 and Tregs have been implicated as key players in MS, and a functional imbalance of these cell 
types is increasingly recognized as a key etiological factor in this disease progression. Tregs are a 
subpopulation of CD4, CD25, FoxP3 expressing T cells that are vital to keep the immune system in 
check, help avoid immune-mediated pathology, and contain unrestricted expansion of effector T-cell 
populations, which results in maintaining tolerance to self-antigens and disease remission. MSCs have 
been reported to induce the production of IL-10 by peripheral DCs, which, in turn, trigger the 
generation of Tregs [40,41]. In addition, in vitro, MSCs can directly induce the proliferation of Tregs 
through release of the immunomodulatory HLA-G isoform HLA-G5 [42]. Taken together, MSCs have 
the capacity to modulate the intensity of an immune attack in MS by inhibiting antigen-specific T-cell 
proliferation and cytotoxicity and promoting the generation of Tregs. 
Keypoints: MSCs can exert anti-inflammatory effects by favoring the generation and proliferation 
of Th2 cells. MSc can also promote self-tolerance by inhibiting the dendritic cell ability to become 
antigen presenting cells. 
Recent studies also suggest that activated T cells are not the only targets of MSCs. The striking 
disease attenuation seen after systemic administration of MSCs in EAE mice is thought to be in part 
mediated by the induction of peripheral tolerance [30] through the inhibition of dendritic cell 
maturation and function [43,44]. Since dendritic cells are the main antigen presenting cells for T-cell 
responses, MSC-mediated suppression of dendritic cell (DC) maturation would prohibit efficient 
antigen presentation and thus, the clonal expansion of autoreactive T-cells. 
Soluble factors, such as transforming growth factor-beta1 (TGF-β1), hepatocyte growth factor 
(HGF), IL-10, PGE2, heme-oxygenase-1 (HO1), interleukin 6 (IL-6), and soluble HLA-G5, are 
constitutively produced by MSCs [29,42,43,45] or secreted in response to cytokines released by the 
target cells upon interacting with MSC, and mediate the immune modulating effects of MSCs. 
The inflammatory cytokine IL6 appears to play a critical role in both the development of Th17 
response and the inhibition of Treg functions. IL-6 is constitutively produced by MSCs that perform 
their effects in an autocrine or paracrine manner on the BM-MSCs themselves and on surrounding 
cells. In RRMS patients, functionally active Treg cells are unable to control the proliferation of 
autoreactive T effector cell (Teff) efficiently. This unresponsiveness is thought to be caused by 
Int. J. Mol. Sci. 2015, 16 9290 
 
 
accelerated production of IL-6, and elevated IL-6 receptor expression in CD4+ and CD8+ Teff cells. 
Exogenous IL-6 can change the kinetics of IL-6 production and induce a positive feedback loop in  
Teff from therapy-naïve MS patients [46]. Moreover, IL-6 signaling acts as a switch for MSC 
immune-modulation of macrophages. In the presence of IL-6, MSCs polarized macrophages towards 
M2 (alternatively activated macrophage phenotype) anti-inflammatory phenotype [47], while in the 
absence of IL-6, MSCs favored M1 (classically activated macrophage phenotype) polarization, which 
is characterized by IFN-γ, TNF-α, and CD40L expression. 
Recent reports showed that MSCs derived from human embryonic stem cells alleviate clinical 
symptoms in a mouse EAE model, significantly superior to human bone-marrow-derived MSCs 
(BM-MSCs). Increased IL-6 production could enhance inflammation in EAE by directing mouse Th17 
differentiation [48]. Human BM-MSCs plus the anti-human interleukin-6 antibody remarkably 
attenuated clinical symptoms in EAE mice compared to IL-6 antibody alone or BM-MSCs plus isotype 
control antibody [49]. Downregulation of IL-6 secretion in MSCs may provide a novel strategy to 
improve MSC-based therapy, and gene silencing technology as a potent weapon could be employed for 
this purpose. These data point to the complex nature of immune modulation by MSCs, and their 
implication in MS therapy needs to be analyzed carefully. 
Keypoints: IL-6 is constitutively produced by MSCs. Higher levels of IL-6 secretion by BM-MSCs 
relative to human embryonic stem cell (hESC)-MSCs have been shown to contribute to the compromised 
ability of BM-MSCs to modulate EAE disease severity. Human BM-MSCs plus the anti-hIL-6 antibody 
remarkably attenuated clinical symptoms in EAE mice. These data point to the complex nature of 
immune modulation by MSCs in the inflammatory milieu. 
HGF is thought to mediate the tolerogenic effects of MSC-stimulated in EAE [50], as systemic 
administration of HGF can ameliorate EAE by inducing tolerogenic dendritic cells (DCs). 
Administration of human MSC conditioned medium (hMSC-CM) containing HGF reduced CNS 
inflammation and clinical deficits in EAE. Interestingly MSCs derived from MS patients, exhibited 
downregulation of HGF genes expression and decreased secretion of IL-10 and TGF-β in supernatants, 
compared to MSC from healthy donors. These might explain the relatively dampened immunomodulatory 
and immunosuppressive activities of bone-marrow MSCs derived from MS patients [51]. Exogenous 
MSC can be devoid of this defect. Overall, HGF derived from MSC is a promising candidate for the 
treatment of MS and other T cell-mediated autoimmunity and neurodegeneration. 
11. Interaction of Endogenous MSCs and the Inflammatory Environment in EAE Determines 
the Outcome of Autoimmune Response 
Recent studies have demonstrated that MSCs themselves underwent autophagy in response to the 
inflammatory environment during their application for EAE treatment. Inflammatory cytokines,  
such as IFN-γ and TNF-α, induced autophagy and regulated the immunomodulatory function of  
MSCs [52]. Inhibition of autophagy in MSCs increased their immunosuppressive effects on T cell-mediated 
EAE [53]. These facts indicated that the interaction between MSCs and the inflammatory 
microenvironment determines the outcome of MSC-mediated therapy. 
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12. MSC-Derived Microvesicles (MVs) as Therapeutic Vehicle 
MSCs can also function as attractive vehicles for cell and gene therapeutic applications. In 
particular, MSC-derived microvesicles (MVs), tiny vesicle like structures of cytoplasm surrounded by 
a membrane, can serve as a vehicle to transfer protein, coding and noncoding RNAs to target cells, 
altering the gene expression, proliferation, and differentiation of the recipient cells [54]. Several 
reports indicate that the regenerative effect of MSCs can be reproduced by MVs isolated from their 
culture medium [55]. In a rat model of unilateral acute kidney injury (AKI), the administration of MSCs 
derived-MVs promoted renal function recovery. MVs deliver RNA into injured tubular cells and induce 
HGF synthesis via RNA transfer, thereby facilitating tubular cell dedifferentiation and regeneration [56]. 
Other recent evidence implicated that the immunomodulatory effects of MSCs are also partially 
mediated by soluble MVs. MVs-based regeneration therapy represent a promising opportunity to 
develop novel cell-free therapy approaches that might evade the obstacles and risks associated with the 
use of native or engineered stem cells [57]. 
Since MSCs could impact the fate of surrounding cells and microenvironments via cell-cell contact 
and soluble factors, the question whether the inflammatory microenvironment and cytokines secreted 
by inflammatory cells or other cells localized within the CNS exert influence on the biological 
properties of MSCs and therapeutic effects of transplanted cells is of great importance for further study. 
13. Clinical Trials in MS Using MSCs 
Numerous clinical trials were conducted in the past several years, and encouraging results supported 
the feasibility and safety of MSC therapy [58]. In a phase II study, nine RRMS patients received 
intravenous infusion of BM-MSCs for six months, and the results indicated that patients treated with 
MSCs had a trend to lower cumulative number of gadolinium-enhancing lesions (GEL) on magnetic 
resonance imaging (MRI), while non-significant decrease of the frequency of Th1 cells in peripheral 
blood of MSCs treated patients was observed [59]. 
In another open-label phase 2a trial designed to assess the safety and efficacy of autologous MSCs 
as a feasible neuroprotective treatment for SPMS, ten patients with SPMS involving the visual 
pathways were recruited and received IV injection of autologous BM-MSCs, and six months after 
treatment, improvement in visual acuity and visual evoked response latency were observed [60]. These 
results are consistent with the neuroprotective effect of MSCs by promotion of endogenous 
oligodendrogenesis and remyelination [22] 
In 2015, a Phase I neural stem cell clinical has been initiated with 20 RRMS patients, to study the 
safety and efficacy of autologous MSC derived neural progenitor cells. Intrathecal injections of 
expanded MSC-neural precursor cell (NPC) will be done over a six-month period, and patients will be 
followed for 27 months. The secondary objective of this trial is to measure the efficacy over a period 
of 36 months. 
14. Induced Pluripotent Stem Cell (iPSCs) 
In 2006, Takahashi and Yamanaka’s ground breaking research led to the generation of induced 
pluripotent stem cells (iPSCs) by reprogramming of mouse fibroblasts back into an embryonic stem 
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cell-like state [13]. iPSCs were obtained by the over-expression of a combination of four genes: 
Oct3/4, Sox2, c-Myc, and Klf4 in mouse fibroblasts. Subsequently, scientists succeeded in generating 
iPSCs from adult human dermal fibroblasts with the same four factors. iPSCs are very similar to ESCs 
with respect to their morphology, gene expression, self-renewal, telomerase activity, proliferation, and 
their capacity to differentiate into cell types of the all three germ layers both in vitro and in teratomas [61]. 
The iPSC technology is currently being used successfully to generate different neuronal cells types 
which are capable of producing fully functional cells. Specific patient iPSC-derived cells can 
recapitulate many pathological features of disease at the molecular level, and thus offers a unique 
platform to model and study many aspects of neurodegenerative “disease-in-a-dish” (Figure 2). This 
could ultimately lead to new insights in disease pathology and developments of novel drugs. For 
example, patient-specific iPSCs are proving useful and efficient in distinguishing individuals that are 
likely to respond to new therapeutics, and seem to be accurately predicting toxicity and efficacy in 
comparison to animal models [62] The recent improvements in generating autologous iPSCs from 
almost any somatic cell type has brought autologous cell therapies at the fore front of clinical research. 
In 2011, researchers differentiated mouse iPSCs successfully into neural precursor cells (NPCs) and 
oligodendrocyte precursor cells (OPCs) that could develop into mature, myelinating oligodendrocytes  
in vitro as well as in vivo [42]. This paves the way for autologous cell replacement, since iPSCs are 
obtained from a patient’s own tissues, there will be minimal risk of immunological rejection [63].  
As an emerging therapeutic method for MS, iPSCs need to be cultured in vitro to harvest fully 
differentiated, expandable and functional NPCs or OPCs for implantation purposes. [64] 
 
Figure 2. The scientific rationale behind human iPSC-based therapeutics. The underlying 
concept is that a patient’s own skin fibroblast cells could be epigenetically reprogrammed 
back into induced pluripotent stem cells. The primary dermal fibroblasts (left image)  
from biopsy samples can be reprogrammed into iPSCs (bottom image), which can be 
differentiated into NPCs, and subsequently into OPCs, neurons and astrocytes (right image), 
and then autologously transplanted back into the original individual, at a low risk of immune 
rejection. The future goal of the iPSC-based cell therapy is to use iPSCs-derivatives to 
develop personalized neuroregenerative and immunomodulatory therapies. MS: multiple 
sclerosis; NPC: neural precursor cells; OPC: oligodendrocyte precursor cells; iPSCs: 
induced pluripotent stem cells. 
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15. Effect of iPSCs Derived Neural Precursor Cells (NPCs) in EAE 
In order to assess the therapeutic potentials of iPSCs in MS, mouse iPSC-derived neural precursor 
cells (miPSC-NPCs) have been tested for its ability to generate OPC and remyelinate in the mouse EAE 
model. The miPSC-NPCs transplanted intrathecally in presymptomatic mice with EAE significantly 
ameliorated clinical and pathological features of EAE [65]. However, the immediate efficacy was  
found to be mostly due to the neuroprotective effect of the transplanted miPSC-NPCs, and not  
through remyelination. The neuroprotective effects were in part through the secretion of leukaemia 
inhibitory factor (LIF) that promoted viability of endogenous OPC and remyelination by endogenous 
oligodendrocytes [65]. 
16. Mechanisms of Action of iPSC–Neural Stem Cells (NSCs): Candidate Factors 
Recent studies have shown that transplanted miPSC-NPCs exert the neuroprotective effect not 
through cell replacement, but through the secretion of leukaemia inhibitory factor (LIF) that promotes 
survival, differentiation and the remyelination capacity of both endogenous oligodendrocyte precursors 
and mature oligodendrocytes in the EAE model [65]. LIF, is a member of the IL-6 cytokine family, 
and is implicated significantly in the pathophysiology of MS. Recent evidence demonstrates a crucial 
role of LIF in neuroprotection and axonal regeneration as well as the prevention of demyelination [66,67]. 
Levy et al. 2015, demonstrated that expression of the LIF receptors was strongly increased on immune 
cells of RRMS patients, whereas, the secreted LIF levels from immune cells of RRMS patients were 
downregulated compared to healthy controls. This immune dysregulation in patients with RRMS is 
thought to be associated with insufficient remyelination and neurogenesis in MS lesions [68]. LIF 
treatment potently boosted the number of regulatory T cells (Tregs) in MS patients with low serum 
levels of IL-6 [69]. Also, a balance between LIF and IL-6 levels is thought to be crucial for 
maintaining the balance between pathogenic Th17 cells vs beneficial Treg cells. In the EAE model a 
shift in the LIF/IL-6 balance in favor of LIF by overexpression of LIF, increased the number of Tregs 
in the CNS during active autoimmune responses and reduced the clinical signs of EAE. Overall, these 
data show that increasing the local levels of LIF in the CNS can down-regulate the autoimmune 
response. The process of neuroinflammation attracts miPSC-NPCs to the site of myelin damage and 
fosters such cells to secrete LIF upon inflammatory stimuli. This in turn has been shown to promote 
endogenous OPC survival and maintain functionality of mature oligodendrocytes. These studies 
provide further impetus for the use of iPSC-NPCs as a novel treatment for MS and other autoimmune 
diseases [69]. Exogenously infused LIF has limited ability to cross the blood–brain barrier and has 
pleiotropic actions outside the CNS making the NPC an ideal choice for delivering LIF. The 
miPSC-NPCs also appear to help preserve the BBB permeability and integrity and restrict the 
continuous CNS recruitment of encephalitogenic blood-borne inflammatory cells [70]. 
17. iPSCs Derived Oligodendrocyte Precursor Cells (OPCs) as a Therapeutic Candidate for MS 
An effective therapeutic strategy for the treatment of demyelinating diseases such as multiple 
sclerosis would require the replacement of glial precursor cells, namely OPCs. Subsequently, a number 
of strategies have been developed for the cell-based repair of demyelinated lesions in the CNS [71,72]. 
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In particular, human OPCs capable of maturation and myelination have been derived from both fetal and 
adult human brain tissue [73–75], as well as from human embryonic stem cells (hESCs) [76–78], and 
have proven effective in experimental models of both congenitally dysmyelinated [74,79,80] and adult 
demyelinated brain [81]. Yet the successes in efficacy, has been complicated by massive immune 
rejection seen with allogenic cells, and thus far hindered the use of allogeneic human cells as transplant 
vectors. The issue of transplant rejection is especially problematic in case of MS, in which the 
inflammatory processes underlying these disorders can present an intrinsically hostile environment to 
any allogeneic grafts [82]. 
To establish a potential autologous source of these cells, Wang et al. successfully generated  
OPCs from three human induced pluripotent stem cell (hiPSC) lines [83]. These highly enriched 
oligodendrocyte lineage transcription factor 2/platelet derived growth factor receptor alpha/NK2 
homeobox 2/sex determining region Y-box 10 (OLIG2+/PDGFRα+/NKX2.2+/SOX10+) human OPCs, 
efficiently differentiated into both myelinogenic oligodendrocytes and astrocytes, in vitro and  
in vivo, and were able to rescue a hypomyelinated mouse model. Neonatally engrafted human 
iPSC-OPCs robustly myelinated the brains of myelin basic protein (MBP)-deficient shiverer mice, and 
significantly increased the life span of these mice. The efficiency of myelination by human iPSC-OPCs 
was higher than that previously observed using fetal tissue-derived OPCs, and no tumors from these 
grafts were noted as long as 36 weeks after transplant. This seminal study has provided great impetus 
to the feasibility of using human iPSC-derived OPCs in treating MS. The success of their protocol in 
all three lines used in this study, suggest its broad range applicability, while the high efficiency 
gliogenesis afforded by this strategy indicates its robust nature. Further studies are urgently needed 
regarding the development and functional characterization of OPCs derived from different types of MS 
patients. It remains to be seen if these OPCs retain the same functionality as iPSC-OPCs derived from 
healthy subjects. In 2014, Douvaras et al. developed a rapid, highly efficient and robust protocol by 
which they generated myelinating oligodendrocytes from primary progressive MS, through iPSC 
technology [46]. The protocol involved generation of iPSCs from skin biopsies, followed by neural 
induction by dual Sme mothers against decapentaplegic (SMAD) inhibition and exposure to retiniods 
from the beginning of differentiation, which led to generation of Olig2-expressing progenitors and  
a high number of OPCs in about 11 weeks. So far we have not come across any reports on the effects 
of iPSC-derived OPCs in the EAE model. 
Although MS results in death of mature oligodendrocytes (OLs), there is ample evidence that 
endogenous OPCs proliferate robustly in an attempt to differentiate and remyelinate the brain during 
relapses in early disease. However, these OPC are inhibited from terminal differentiation, and 
therefore remyelination fails. Later in the disease course, the OPC pool gradually disappears, and thus 
cell replacement could be of great benefit at that stage. The success of cell therapy, however, relies on 
the fact that exogenously transplanted OPCs would be able to terminally differentiate and mature to 
make myelin. Further research is needed in this area to characterize the fate of transplanted OPCs in 
the inflammatory environment. 
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18. Modelling MS Pathology though the iPSC Platform 
Human dermal fibroblasts from RRMS patients have been reprogrammed to pluripotent state  
via retroviral transduction. The MS-iPSCs can successfully differentiate into mature astrocytes, 
oligodendrocytes and neurons with normal karyotypes [84]. Although MS-iPSC-derived neurons 
presented some differences in their electrophysiological characteristics as compared to the control 
hESCs, they did exhibit properties of functional neurons, with robust resting membrane potentials, 
large fast tetrodotoxin-sensitive action potentials and voltage-gated sodium currents. These results 
demonstrated for the first time that iPSCs derived from disease-state patients can be generated  
and differentiated into mature neural lineages. In 2014, Douvaras et al. reported the generation of 
iPSCs from skin biopsies from four PPMS patients and their efficient differentiation to functional 
oligodendrocytes, as demonstrated by in vivo myelination in the shiverer mouse. PPMS-OPCs also 
differentiated into mature oligodendrocyte which formed dense compact myelin resembling normal 
myelin in EAE mice, as efficiently as iPSC-derived OPCs from healthy subjects [45]. The general 
protocol for induction of iPSCs into OPCs and mature oligodendrocyte in vitro is very inefficient and 
required 120–150 days in culture. An improved protocol uses at least 75 days to harvest the OPCs [45]. 
Given the rapid progress in this emerging field, iPSCs may demonstrate great potential in clinical use 
for MS treatment. 
19. Risks and Disadvantages with the Use of MSCs and iPSCs in Clinical Applications 
The epigenetic memory of iPSCs is a signature acquired from parental cells and the reprogramming 
process, which restricts the ability of iPSCs to differentiate and form cells from alternative lineages 
and creates predisposition to redifferentiate into their original cell type [85]. These iPSC epigenetic 
signatures can be transmitted to their progeny even after differentiation and may affect the function of 
iPSC-derived cells [86]. Due to selective pressures of culture conditions and the consequences of 
reprogramming to produce iPSCs, including genetic mutations and overexpression, it will be important 
to improve reprogramming protocols to overcome these hurdles and generate genetically stable iPSCs. 
20. Conclusions 
Stem cell therapy using MSCs or iPSCs shows great potential as treatment for MS. However, there 
are many issues and limitations that need to be resolved. The specific cell stage to be transplanted, proper 
characterization of the cell type to be administered, in vivo fate of transplanted cells in different 
inflammatory models, dose, route of administration, duration of therapeutic effect and genomic stability 
of stem cells need further exploration and quantification. Patient-derived iPSCs also represent a novel 
tool in modeling MS pathology enabling the confirmation of positive responders to new pharmacotherapy 
and implementation of patient-specific therapeutic managements. 
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